FDA Expected to Miss Savara Drug Review Deadline
The FDA will not meet its Nov. 22, 2026, target date for reviewing Savara’s application for molgramostim, an investigational inhaled treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease. The review is continuing, but the agency has not provided a new decision date or explained the delay. The missed milestone does not indicate that the FDA has rejected the treatment or reached a negative conclusion about it, though the lack of a timeline has created uncertainty for the company and investors. Savara says it will continue working with the agency to complete the review.




